Annovis Bio appoints Henry Hagopian III as CFO, replacing Jeff McGroarty who departs

Annovis Bio, Inc.

Henry Hagopian III appointed CFO effective Aug 29, 2022; Jeff McGroarty departs to pursue other interests.
Hagopian has 30 years of finance experience, most recently SVP Finance & Treasurer at Organogenesis (ORGO).
Compensation includes $375,000 base salary, 35% target bonus, and 120,000 stock options at $11.55 exercise price.
Company highlights advancement of lead drug buntanetap into Phase 3 trials for neurodegenerative diseases.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey McGroarty

Chief Financial Officer

ANVS · Annovis Bio, Inc.

Effective: 2022-08-29
Successor: Henry Hagopian III
Filed: August 30, 2022, 7:59 PM ET

Mr. McGroarty will leave the Company to pursue other interests.

Appointed

Henry Hagopian III

Chief Financial Officer

ANVS · Annovis Bio, Inc.

Effective: 2022-08-29
Successor: Jeffrey McGroarty
Filed: August 30, 2022, 7:59 PM ET

On August 29, 2022, the Board of Directors of Annovis Bio, Inc. (the “Company”) appointed Henry Hagopian III, age 54, as Chief Financial Officer of the Company, effective immediately, to replace Jeffrey McGroarty.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey McGroarty departed as Chief Financial Officer at Annovis Bio, Inc..

Action: left
Role: Chief Financial Officer

Exact text from the filing

Mr. McGroarty will leave the Company to pursue other interests.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Henry Hagopian III was appointed as Chief Financial Officer at Annovis Bio, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On August 29, 2022, the Board of Directors of Annovis Bio, Inc. (the “Company”) appointed Henry Hagopian III, age 54, as Chief Financial Officer of the Company, effective immediately, to replace Jeffrey McGroarty.

View on SEC.gov

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-095769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.